Announced sale of FibroGen China to AstraZeneca for a total consideration of approximately $160 million Transaction expected to close by mid-2025 Upon close of sale of FibroGen China, cash runway exte ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback